Acne Vulgaris Market By Therapeutic Class (Retinoid (Topical Retinoid & Combination Retinoid and Oral Retinoid (Isotretinoin)), Antibiotic (Topical Antibiotic & Combination Antibiotics, and Oral Antibiotics), Salicylic Acid, Benzoyl Peroxide, and Others), By Product (Mask, Creams & Lotions, Cleansers & Toners, and Others), By Formulation (Topical Medication and Oral Medication), By Acne Type (Non-inflammatory acne and Inflammatory acne), By Distribution Channel (Retail Drug Store, Hospital Pharmacies, and E-Commerce), and Geography

Acne Vulgaris Market Size was valued at USD 9.2 billion in 2022 and is poised to grow at a significant CAGR of 5.1% from 2023-2029. Acne vulgaris is a very common chronic skin condition involving blockage or inflammation of the sebaceous gland. It occurs mostly in teenagers and young adults. Pus-filled pimples, inflame, red bumps, and uninflamed blackheads are very common symptoms of acne vulgaris. Treatment includes over-the-counter creams, cleansers, retinoids, antibiotics, salicylic acid, and benzoyl peroxide.

The rising prevalence of acne among teenagers & young adults is driving the global market of acne vulgaris. For instance, according to NCBI, Acne is estimated to affect 9.4% of the global population, making it the eighth most prevalent disease worldwide. Several clinical studies have reported a prevalence of adolescent acne ranging from 81 to 95 percent in young men and 79 to 82 percent in young women. Clinical approval & launch of new drugs are propelling the market growth.  Despite all of the driving factors, some factors are limiting the market growth among them most influential restrain of the market is the side effects of acne treatment drugs. Some medications for acne vulgaris can cause severe allergic reactions, irritations, nausea, vomiting, etc.

Moreover, available treatment options and the introduction of new products for acne treatment such as retinoids, and antibiotics are increasing awareness all over the world. Efficient marketing is expected to propel the market. Also, hormonal therapy has potential growth opportunities in the future. The growing demand for hormonal therapies and recurring investments in the research and development sector for new drugs and therapies will exponentially grow the global acne vulgaris market. North America is dominating the market based on the region due to rising concerns about derma products. 

Acne Vulgaris Market Key Development:

• In July 2022, Glenmark Pharmaceuticals launched its topical Minocycline 4% gel for the treatment of moderate to severe acne under the brand MINYM.
• In Mar 2022, Galderma announced the launch of Twyneo (tretinoin 0.1% and benzoyl peroxide 3%) cream for the topical treatment of acne vulgaris in patients 9 years of age and older.